A European Medicines Agency (EMA) panel recommended Zybrivo for first-line use with chemotherapy in certain adults with non-small cell lung cancer, advancing Innovent Biologics' drug toward possible European Union authorization.
The agency's Committee for Medicinal Products for Human Use (CHMP) adopted its opinion Nov. 12. The proposed use covers adults with non-squamous non-small cell lung cancer (NSCLC) whose tumors lack EGFR or ALK genomic abnormalities. It includes metastatic disease and locally advanced cancer unsuitable for surgery or chemoradiation intended to cure. The regimen combines Zybrivo (sintilimab) with pemetrexed and platinum-based chemotherapy.
The Phase 3 ORIENT-11 study enrolled 397 patients in a randomized, double-blind comparison. A total of 266 received sintilimab plus chemotherapy and 131 received placebo plus chemotherapy. The original study publication reported median progression-free survival of 8.9 months in the sintilimab group and 5.0 months in the placebo group. The hazard ratio was 0.482, with a 95% confidence interval of 0.362 to 0.643.
A later final overall-survival analysis found median survival of 24.2 months with sintilimab and 16.8 months with placebo. It used data through Sept. 15, 2021, with median follow-up of 30.8 months. Under the study protocol, 47% of patients initially assigned to placebo switched to sintilimab alone.
The EMA lists anemia, low neutrophil, white blood cell and platelet counts, reduced appetite, nausea, fatigue, elevated liver enzymes, fever, hypothyroidism and rash among the most common side effects. The agency identifies Fortvita Biologics (Ireland) Limited as the applicant. Innovent's 2025 annual report lists Fortvita as an indirectly held subsidiary with a 100% attributable equity interest as of Dec. 31, 2025.
The European Commission's marketing authorization decision remains pending. Innovent announced the panel's opinion Nov. 15 and said the Commission was expected to decide in the coming months.


